Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Risk stratification in metastatic seminoma

Peter Albers • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Testicular Cancer Cisplatin Etoposide

Peter Albers, MD, University Hospital of Düsseldorf, Düsseldorf, Germany, discusses risk stratification in metastatic seminoma, one of two predominant histologic subtypes of testicular cancer. Dr Albers focuses on tailoring treatment for seminoma patients as well as reducing treatment burden. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Peter Albers

3:14
Novel MRI approach for prostate cancer screening
Peter Albers • 8 Jul 2021
3:40
Surgery in metastatic germ cell tumors to reduce disease burden and improve long-term outcomes
Peter Albers • 8 Jul 2021
1:34
Current state of prostate cancer screening in Europe
Peter Albers • 8 Jul 2021
1:57
Challenges in prostate cancer screening
Peter Albers • 8 Jul 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals